|Last Price$77.51||Day Change (%)0.30%|
|Open Price$77.15||Day Change ($)0.23|
|Day Range76.51–77.64||52-Week Range64.33–90.63|
As of Wed 04/23/2014 12:32 PM EST | USD
UPDATE: I have no qualms about taking Gilead's $84,000 drug
Corporate credit spreads are fairly valued--albeit at the tight end of the range that we view as fairly valued.
If deal stands, would mark another win for Schlichter.
The information and opinions presented herein are not meant to be taken as investment advice. We do our best to make sure the information presented in this article is factual and correct, but Zacks cannot be held responsible for any losses incurred from investment transactions made based on ...
After setbacks in the Affordable Care Act's rollout are resolved, we think one 4-star managed care firm is particularly well-positioned to take advantage of the public exchanges over the longer term, says Morningstar's Vishnu Lekraj.
Increased investor inflows and portfolio reshuffling (driven in part by a fairly valued market), has added breadth to the high-conviction and new-money purchases we've seen so far from our top managers.
Get our sector-by-sector take on the bond markets, plus our five best bond ideas.
Plus, Schwab receives Wells Notice, Fidelity Magellan adds gold, and more.
AIM board chairman Bruce Crockett tells us what goes on at AIM's board meetings.